Annexon ARCHER Ph2: ANX007 shows stat-sig vision loss protection, primary lesion growth endpoint missed

Annexon, Inc.

ANX007 monthly reduced risk of ≥15-letter BCVA loss by 72% (p=0.006); pooled 59% (p=0.008).
Primary endpoint GA lesion growth rate reduction not met: monthly 6.2% (p=0.526), EOM 1.3% (p=0.896).
ANX007 well-tolerated; 3 SAEs endophthalmitis (injection-related), 3 SAEs intraocular inflammation suspected treatment-related.
First complement therapy to show preservation of visual function in a prospective 12-month GA trial.
Company plans regulatory engagement for optimal path forward; webcast today 1:30pm PT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.